LYEL · Insider Trading

Lyell Immunopharma, Inc. Common Stock

Every open-market purchase and sale reported by LYEL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
4
code P
Sales
27
code S
Reporting Insiders
18
current holders
LYEL — Recent Form 4 Transactions (latest 2026-11-12)
FiledInsiderRole TypeSharesValue
2026-11-12 Gary K. Lee Chief Scientific Officer Sell −129 −$2.05K
2026-11-12 Lynn Seely President and CEO Sell −545 −$8.68K
2026-11-12 Veronica Sanchez Bulis VP, Corporate Controller Sell −416 −$6.63K
2026-11-12 Stephen J. Hill Chief Operating Officer Sell −88 −$1.40K
2026-11-05 ARCH Venture Fund IX, L.P. 10%+ Owner Buy +2,321,262 +$25.00M
2026-11-05 ARCH Venture Partners XIII, L.P. 10%+ Owner Buy +2,321,262 +$25.00M
2026-10-13 Jarrad Mattieu Aguirre Chief Medical Officer Sell −422 −$3.64K
2026-09-10 David Shook Chief Medical Officer Sell −500 −$6.35K
2026-09-10 Jarrad Mattieu Aguirre Chief Medical Officer A — —
2026-08-25 Gary K. Lee Chief Scientific Officer Sell −1,457 −$22.64K
2026-08-25 Stephen J. Hill Chief Operating Officer Sell −989 −$15.37K
2026-08-25 Lynn Seely President and CEO Sell −9,589 −$149.01K
2026-08-11 Veronica Sanchez Bulis VP, Corporate Controller Sell −621 −$8.91K
2026-08-11 Lynn Seely President and CEO Sell −390 −$5.59K
2026-08-11 Gary K. Lee Chief Scientific Officer Sell −131 −$1.88K
2026-08-11 Stephen J. Hill Chief Operating Officer Sell −89 −$1.28K
2026-07-27 Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner J −38,500 —
2026-07-27 Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner J −44,000 —
2026-07-20 Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner Sell −10 −$137
2026-07-17 Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner Sell −10 −$137
2026-07-01 Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner J −76,000 —
2026-06-18 Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner J −66,500 —
2026-06-15 Lynn Seely President and CEO Sell −388 −$7.34K
2026-06-15 Stephen J. Hill Chief Operating Officer Sell −89 −$1.68K
2026-06-15 Veronica Sanchez Bulis VP, Corporate Controller Sell −217 −$4.10K
2026-06-15 Gary K. Lee Chief Scientific Officer Sell −130 −$2.46K
2026-06-12 Mark Bachleda Director A +9,250 deriv. —
2026-06-12 Richard Klausner Director A — —
2026-06-12 Otis W Brawley Director A — —
2026-06-12 Elizabeth G Nabel Director A +9,250 deriv. —
2026-06-12 Cathy Friedman Director A — —
2026-06-12 William Jl Rieflin Director A +9,250 deriv. —
2026-06-12 Sumant Ramachandra Director A — —
2026-06-11 David Shook Chief Medical Officer Sell −1,977 −$24.99K
2026-03-16 Smital Shah Chief Fin. and Bus. Officer A +140,000 deriv. —
2026-03-09 Paul L Berns 10%+ Owner Buy +488,090 +$12.50M
2026-03-09 ARCH Venture Partners IX, LLC 10%+ Owner Buy +488,090 +$12.50M
2026-02-12 Gary K. Lee Chief Scientific Officer Sell −1,671 −$39.08K
2026-02-12 Stephen J. Hill Chief Operating Officer Sell −1,236 −$28.91K
2026-02-12 Lynn Seely President and CEO Sell −7,455 −$174.37K
2026-02-11 Mark A Meltz General Counsel A +50,000 deriv. —
2026-02-11 Veronica Sanchez Bulis VP, Corporate Controller MIXED +8,496 −$5.87K
2026-02-11 Lynn Seely President and CEO MIXED +19,562 −$10.13K
2026-02-11 Stephen J. Hill Chief Operating Officer MIXED +3,891 −$2.52K
2026-02-11 Gary K. Lee Chief Scientific Officer MIXED +3,853 −$3.40K
2026-02-11 David Shook Chief Medical Officer A — —
2026-01-06 Veronica Sanchez Bulis VP, Corporate Controller Sell −2,072 −$74.18K
2025-11-12 Stephen J. Hill Chief Operating Officer Sell −95 −$1.53K
2025-11-12 Veronica Sanchez Bulis VP, Corporate Controller Sell −239 −$3.85K
2025-11-12 Lynn Seely President and CEO Sell −412 −$6.64K
LYEL — Current Insider Holders
InsiderRole Shares HeldValue
ARCH Venture Partners XIII, L.P. 10%+ Owner 3,747,790 $51.06M
ARCH Venture Fund IX, L.P. 10%+ Owner 3,747,790 $51.06M
Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner 2,774,980 $37.81M
Keith Crandell 10%+ Owner 1,820,634 $24.81M
ARCH Venture Partners IX, LLC 10%+ Owner 1,426,528 $19.44M
Paul L Berns 10%+ Owner 1,426,528 $19.44M
Richard Klausner Director 190,557 $2.60M
Lynn Seely President and CEO 63,354 $863.17K
Charles W. Newton Chief Financial Officer 25,306 $344.78K
David Shook Chief Medical Officer 20,423 $278.26K
Jarrad Mattieu Aguirre Chief Medical Officer 19,857 $270.54K
Cathy Friedman Director 16,818 $229.14K
Stephen J. Hill Chief Operating Officer 16,728 $227.91K
Gary K. Lee Chief Scientific Officer 16,091 $219.23K
Veronica Sanchez Bulis VP, Corporate Controller 14,383 $195.96K
Sumant Ramachandra Director 10,000 $136.25K
Matthew Lang Chief Business Officer 8,125 $110.70K
Otis W Brawley Director 1,782 $24.28K
LYEL Insider Trading FAQ
Who are the insiders at LYEL?
18 officers, directors and 10%+ beneficial owners currently report holdings in LYEL via SEC Form 4.
Are LYEL insiders buying or selling?
Across the 50 most recent Form 4 filings for LYEL, 4 were open-market purchases (code P) and 27 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is LYEL insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent LYEL filing is dated 2026-11-12.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the LYEL quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.